2022年COVID-19疫苗檢驗封緘放行分析   全文下載

Annual Report on Batch Release of COVID-19 Vaccine in Taiwan, 2022

自2019年於中國武漢首次發現SARS-CoV-2，數年間COVID-19疫情在全球依然持續傳播，病毒株亦不斷變異，和病毒共存已是無法改變之趨勢。目前疫苗已被證實能有效減緩COVID-19重症和降低死亡風險，因應緊急防疫需求，2021年計有4款疫苗核准專案輸入及製造，2022年為提升全國疫苗涵蓋率，另核准Moderna COVID-19 Vaccine Spikevax 0.10 mg/mL、Moderna雙價疫苗-原型株/BA.1、Moderna雙價疫苗-原型株/BA.4/ BA.5、BioNTech COVID-19 Vaccine Comirnaty 10μg/dose、BioNTech COVID-19 Vaccine Comirnaty 3μg/dose及Novavax COVID-19 Vaccine Nuvaxovid等3家製造廠共計6款COVID-19疫苗專案輸入許可。2022年衛生福利部食品藥物管理署（下稱食藥署）於COVID-19疫苗共放行37批次計28,253,921劑，本研究藉由分析放行趨勢與各疫苗廠牌不同劑型放行數量，作為民眾未來疫苗接種計劃的參考。

Since the first discovery of SARS-CoV-2 in Wuhan, China in 2019, the COVID-19 pandemic has spreaded globally over the years, and the virus continues to mutate as well. Co-existing with the virus has become an inevitable trend. Currently, vaccines have been proven effective in reducing the risk of severe illness and death caused by COVID-19. In response to the urgent need for epidemic prevention, four vaccines were approved for use in 2021. In order to increase the national vaccine coverage rate, additional six COVID-19 vaccines of international companies were issued the Emergency Use Authorization (EUA), including Moderna COVID-19 Vaccine Spikevax 0.10 mg/mL, Moderna COVID-19 Vaccine Spikevax Bivalent Original/Omicron, Moderna COVID-19 Vaccine Spikevax Bivalent Original and Omicron BA.4/BA.5, BioNTech COVID-19 Vaccine Comirnaty 10μg/dose, BioNTech COVID-19 Vaccine Comirnaty 3μg/dose, and Novavax COVID-19 Vaccine Nuvaxovid in 2022. In the same year, 37 batches of COVID-19 vaccine, a total of 28,253,921 doses, have been batch-released by the Taiwan Food and Drug Administration (TFDA). This report reviewed the data of COVID-19 vaccine batch released trends, different vaccine brands and dosages, thus providing reference for vaccination plans.